Quick Answer
Trevi Therapeutics, Inc. reported Cash and Equivalents of $18.91 million for fiscal year 2025.
Trevi Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $18.91M | -44.5% |
| 2024 | $34.10M | +5.2% |
| 2023 | $32.40M | +157.3% |
| 2022 | $12.59M | -65.8% |
| 2021 | $36.83M | -18.2% |
| 2020 | $45.00M | -21.5% |
| 2019 | $57.31M | +695.8% |
| 2018 | $7.20M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $56.87M | +254.3% | -51.4% |
| June 30, 2025 | $117.06M | +803.0% | +504.2% |
| March 31, 2025 | $19.37M | +40.3% | -43.2% |
| December 31, 2024 | $34.10M | +5.2% | +112.4% |
| September 30, 2024 | $16.05M | -38.2% | +23.8% |
| June 30, 2024 | $12.96M | -5.7% | -6.1% |
| March 31, 2024 | $13.81M | +18.5% | -57.4% |
| December 31, 2023 | $32.40M | +157.3% | +24.8% |
- Trevi Therapeutics, Inc. showed a decrease of -44.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Trevi Therapeutics, Inc.’s cash and equivalents has grown by 162.6% (from $7.20 million to $18.91 million).
- The most recent figure is from Trevi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: